These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 13129568)

  • 1. Synthesis of a high-affinity fluorescent PPARgamma ligand for high-throughput fluorescence polarization assays.
    DeGrazia MJ; Thompson J; Heuvel JP; Peterson BR
    Bioorg Med Chem; 2003 Oct; 11(20):4325-32. PubMed ID: 13129568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A rapid, homogeneous, fluorescence polarization binding assay for peroxisome proliferator-activated receptors alpha and gamma using a fluorescein-tagged dual PPARalpha/gamma activator.
    Seethala R; Golla R; Ma Z; Zhang H; O'Malley K; Lippy J; Cheng L; Mookhtiar K; Farrelly D; Zhang L; Hariharan N; Cheng PT
    Anal Biochem; 2007 Apr; 363(2):263-74. PubMed ID: 17335769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety.
    Collins JL; Blanchard SG; Boswell GE; Charifson PS; Cobb JE; Henke BR; Hull-Ryde EA; Kazmierski WM; Lake DH; Leesnitzer LM; Lehmann J; Lenhard JM; Orband-Miller LA; Gray-Nunez Y; Parks DJ; Plunkett KD; Tong WQ
    J Med Chem; 1998 Dec; 41(25):5037-54. PubMed ID: 9836621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors.
    Xu HE; Lambert MH; Montana VG; Plunket KD; Moore LB; Collins JL; Oplinger JA; Kliewer SA; Gampe RT; McKee DD; Moore JT; Willson TM
    Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13919-24. PubMed ID: 11698662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective binding of the fluorescent dye 1-anilinonaphthalene-8-sulfonic acid to peroxisome proliferator-activated receptor gamma allows ligand identification and characterization.
    Zorrilla S; Garzón B; Pérez-Sala D
    Anal Biochem; 2010 Apr; 399(1):84-92. PubMed ID: 20025845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.
    Cobb JE; Blanchard SG; Boswell EG; Brown KK; Charifson PS; Cooper JP; Collins JL; Dezube M; Henke BR; Hull-Ryde EA; Lake DH; Lenhard JM; Oliver W; Oplinger J; Pentti M; Parks DJ; Plunket KD; Tong WQ
    J Med Chem; 1998 Dec; 41(25):5055-69. PubMed ID: 9836622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of a Coumarin-Based PPARγ Fluorescence Probe for Competitive Binding Assay.
    Yoshikawa C; Ishida H; Ohashi N; Itoh T
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33919837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of high throughput screening assays using fluorescence polarization: nuclear receptor-ligand-binding and kinase/phosphatase assays.
    Parker GJ; Law TL; Lenoch FJ; Bolger RE
    J Biomol Screen; 2000 Apr; 5(2):77-88. PubMed ID: 10803607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subtype specific effects of peroxisome proliferator-activated receptor ligands on corepressor affinity.
    Stanley TB; Leesnitzer LM; Montana VG; Galardi CM; Lambert MH; Holt JA; Xu HE; Moore LB; Blanchard SG; Stimmel JB
    Biochemistry; 2003 Aug; 42(31):9278-87. PubMed ID: 12899614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family.
    Cronet P; Petersen JF; Folmer R; Blomberg N; Sjöblom K; Karlsson U; Lindstedt EL; Bamberg K
    Structure; 2001 Aug; 9(8):699-706. PubMed ID: 11587644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
    Henke BR; Blanchard SG; Brackeen MF; Brown KK; Cobb JE; Collins JL; Harrington WW; Hashim MA; Hull-Ryde EA; Kaldor I; Kliewer SA; Lake DH; Leesnitzer LM; Lehmann JM; Lenhard JM; Orband-Miller LA; Miller JF; Mook RA; Noble SA; Oliver W; Parks DJ; Plunket KD; Szewczyk JR; Willson TM
    J Med Chem; 1998 Dec; 41(25):5020-36. PubMed ID: 9836620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design and synthesis of fluorescent PPARalpha/delta co-agonist and its application as a probe for fluorescent polarization assay of PPARdelta ligands.
    Araya Y; Kasuga J; Toyota K; Hirakawa Y; Oyama T; Makishima M; Morikawa K; Hashimoto Y; Miyachi H
    Chem Pharm Bull (Tokyo); 2008 Sep; 56(9):1357-9. PubMed ID: 18758120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligand-induced stabilization of PPARgamma monitored by NMR spectroscopy: implications for nuclear receptor activation.
    Johnson BA; Wilson EM; Li Y; Moller DE; Smith RG; Zhou G
    J Mol Biol; 2000 Apr; 298(2):187-94. PubMed ID: 10764590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma.
    Agostini M; Gurnell M; Savage DB; Wood EM; Smith AG; Rajanayagam O; Garnes KT; Levinson SH; Xu HE; Schwabe JW; Willson TM; O'Rahilly S; Chatterjee VK
    Endocrinology; 2004 Apr; 145(4):1527-38. PubMed ID: 14657011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a novel PPARγ ligand screening system using pinpoint fluorescence-probed protein.
    Nagai H; Ebisu S; Abe R; Goto T; Takahashi N; Hosaka T; Kawada T
    Biosci Biotechnol Biochem; 2011; 75(2):337-41. PubMed ID: 21307572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined biophysical and cell-based approaches for the assessment of ligand binding to PPARγ.
    Zorrilla S; Pérez-Sala D
    Methods Mol Biol; 2013; 952():237-52. PubMed ID: 23100238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a PPARgamma agonist, GI262570, on renal filtration fraction and nitric oxide level in conscious rats.
    Yang B; Clifton LG; McNulty JA; Chen L; Brown KK; Baer PG
    J Cardiovasc Pharmacol; 2003 Sep; 42(3):436-41. PubMed ID: 12960690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A fluorescent indicator to visualize ligand-induced receptor/coactivator interactions for screening of peroxisome proliferator-activated receptor gamma ligands in living cells.
    Awais M; Sato M; Umezawa Y
    Biosens Bioelectron; 2007 May; 22(11):2564-9. PubMed ID: 17095203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A yeast two-hybrid technology-based system for the discovery of PPARgamma agonist and antagonist.
    Chen Q; Chen J; Sun T; Shen J; Shen X; Jiang H
    Anal Biochem; 2004 Dec; 335(2):253-9. PubMed ID: 15556564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma.
    Wang Y; Porter WW; Suh N; Honda T; Gribble GW; Leesnitzer LM; Plunket KD; Mangelsdorf DJ; Blanchard SG; Willson TM; Sporn MB
    Mol Endocrinol; 2000 Oct; 14(10):1550-6. PubMed ID: 11043571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.